• About
    • Company Profile
    • Company Introduction
    • R&D
      • Core Technology
      • PTS: Functional Mechanism
      • R&D Center
      • Paper Publish
    • History
    • Our Team
    • Partnership
      • Partnerships – Human Indication
      • Partnerships – Animal Drugs
  • News
    • Coming event
    • News Focus
    • Activites section
    • Announcement
  • Products
    • Para-Toluenesulfonamide (PTS)
      • PTS: Functional Mechanism
      • Product Features
      • Comparison with existing cancer treatments
    • Market Position
    • R&D
      • PTS100
      • PTS500
      • PTS02
      • GWA103
      • GWA106
  • Clinical Trials
    • Product progress
    • Compassionate use
      • Compassionate use cases
  • Partnership
    • Partnerships – Human Indication
    • Partnerships – Animal Drugs
  • Animals
  • Medical
    • Cosmetics
      • MAGIC SKIN GEL
        • DM
    • ROAN
      • DM
    • Pet Gel-Speedling
  • Investors
    • Important news
      • 2026/9/24 To announce in accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
      • 2026/9/19 On behalf of Tianjin Chase Sun Jiandakang, PTS Phase II HCC trial abstract in China accepted for presentation at ESMO Asia 2026.
      • 2026/9/10 On behalf of subsidiary Tianjin Chase Sun Jiandakang, PTS-302 NDA was accepted for review in Morocco.
      • 2026/09/05 Gongwin Pet Biopharm: Pet anti-cancer drug Gwa103 passes MOA technical review for NDA.
      • 2026/8/25 In accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
      • 2026/8/25 Company's Board of Directors has approved the consolidated financial report for the Second quarter of year 2026
    • Financial area
      • Annual Report
      • Monthly Revenue
        • 2026
        • 2025
        • 2024
      • Consolidated Financial Reports
    • Shareholders area
    • Corporate Governance
  • Contact

下載產品DM

  • LINKEDIN
  • YOUTUBE
  • 中文
  • EN

INQUIRY

()
  • 中文
  • EN

下載產品DM

SCROLL DOWN

  • Home
  • Investors
  • Financial area
  • Monthly Revenue
  • 2025
Investors
  • Important news
    • 2026/9/24 To announce in accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
    • 2026/9/19 On behalf of Tianjin Chase Sun Jiandakang, PTS Phase II HCC trial abstract in China accepted for presentation at ESMO Asia 2026.
    • 2026/9/10 On behalf of subsidiary Tianjin Chase Sun Jiandakang, PTS-302 NDA was accepted for review in Morocco.
    • 2026/09/05 Gongwin Pet Biopharm: Pet anti-cancer drug Gwa103 passes MOA technical review for NDA.
    • 2026/8/25 In accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
    • 2026/8/25 Company's Board of Directors has approved the consolidated financial report for the Second quarter of year 2026
  • Financial area
    • Annual Report
    • Monthly Revenue
      • 2026
      • 2025
      • 2024
    • Consolidated Financial Reports
  • Shareholders area
  • Corporate Governance

2025

 

 

2025 Monthly Revenue
   (In thousands of New Taiwan Dollars)
MonthConsolidated Revenue
20252024YoY Change (%)
Jan.2,3811,70139.98%
Feb.2,4471,44069.93%
Mar.2,7842,34618.67%
Apr.3,4852,45741.84%
May2,6273,530-25.58%
Jun.2,6503,742-29.18%
Jul.2,8052,7631.52%
Aug.4,3103,17635.71%
Sep.5,0502,77182.24%
Oct.1,8742,735-31.48%
Nov.2,5912,961-12.50%
Dec.3,5052,68630.49%
Total36,50932,30813.00%
Previous page
Back to list
Next page

TOP

Please enter a product name
  • LINKEDIN
  • YOUTUBE
Gongwin Biopharm Co., Ltd.
TEL +886-2-2503-5282
MAIL info@gongwinbiopharm.com
ADDRESS 3F, No. 80, Sec. 1, Jianguo N. Rd., Zhongshan Dist., Taipei City 10491, Taiwan
  • LINKEDIN
  • YOUTUBE
© 2026 Gongwin Biopharm Co., Ltd. All rights reserved. Designed By  Winho
Privacy policy  |  Sitemap